BioNotebook; clinical updates: Merrimack, AstraZeneca, Flexion
This article was originally published in Scrip
Executive Summary
Merrimack sinks on Phase II fail; AstraZeneca starts Phase III asthma study; and Flexion reports Phase IIb data for FX006.